AstraZeneca shares fall 7% after cancer drug Gefitinib plea shot down


Shares of AstraZeneca Pharma today tumbled over 7 per cent, after the Intellectual Property Appellate Board (IPAB) turned down the drug firm's plea for a patent on the lung cancer drug Gefitinib.

Following the move, shares of the company opened weak and as the trade progressed it tanked 7.38 per cent to Rs 1,449.50 on the BSE.

At NSE, the scrip slipped 7.65 per cent to Rs 1,444.05.

Reacting on the development, the company said it is disappointed and is evaluating its options.

"We are disappointed by the Intellectual Property Appellate Board's decision.

We are confident in the validity of the claims in this patent application and are now evaluating our next steps," AstraZeneca said in a statement.

IPAB on November 26 upheld its earlier decision to refuse AstraZeneca a patent claim in 2007, citing lack of invention.

Decline in the stock was in contrast with a robust stock market where the benchmark index Sensex was trading at 19,093.42, up 251.34 points.

Please read our terms of use before posting comments
TERMS OF USE: The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
comments powered by Disqus